Factors predicting treatment responsiveness and prognosis in node-negative breast cancer. The International (Ludwig) Breast Cancer Study Group.
暂无分享,去创建一个
J. Torhorst | K. Price | R. Golouh | A. Neville | R. Gelber | H. Peterson | J. Säve‐Söderbergh | B. Davis | R. Bettelheim | R. Reed
[1] R. Gelber,et al. A single perioperative adjuvant chemotherapy course for node-negative breast cancer: five-year results of trial V. International Breast Cancer Study Group (formerly Ludwig Group). , 1992, Journal of the National Cancer Institute. Monographs.
[2] M L Lesser,et al. Prediction of early relapse in patients with operable breast cancer by detection of occult bone marrow micrometastases. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] F. Cavalli,et al. Quality-of-Life-Adjusted Evaluation of Adjuvant Therapies for Operable Breast Cancer , 1991 .
[4] A. Lee,et al. Prognostic significance of peritumoral lymphatic and blood vessel invasion in node-negative carcinoma of the breast. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] W. Lane,et al. Node‐negative minimal invasive breast cancer patients are not candidates for routine systemic adjuvant therapy , 1990, Cancer.
[6] Internationalludwigbreastcanc. Prognostic importance of occult axillary lymph node micrometastases from breast cancers , 1990 .
[7] D. Kopans,et al. Medullary carcinoma of the breast. Overdiagnosis of a prognostically favorable neoplasm. , 1990, Archives of surgery.
[8] D. Visscher,et al. Prognostic significance of morphological parameters and flow cytometric DNA analysis in carcinoma of the breast. , 1990, Pathology annual.
[9] T. Maudelonde,et al. CATHEPSIN D: AN INDEPENDENT PROGNOSTIC FACTOR FOR METASTASIS OF BREAST CANCER , 1989, The Lancet.
[10] D. Sedmak,et al. Prognostic significance of cytokeratin-positive breast cancer metastases. , 1989, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.
[11] S Hellman,et al. Pathological prognostic factors in stage I (T1N0M0) and stage II (T1N1M0) breast carcinoma: a study of 644 patients with median follow-up of 18 years. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] W. Blakemore,et al. The content of tumor DNA as an indicator of prognosis in patients with T1N0M0 and T2N0M0 carcinoma of the breast. , 1989, Surgery.
[13] M. Ta,et al. Detection of metastatic breast carcinoma with monoclonal antibodies to cytokeratins. , 1989 .
[14] R. Coombes,et al. The fate of bone marrow micrometastases in patients with primary breast cancer. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] J. Hoehn,et al. Influence of estrogen receptors on survival and recurrence in patients with breast cancer without lymph node metastases. , 1989, Archives of surgery.
[16] C K Osborne,et al. Efficacy of adjuvant chemotherapy in high-risk node-negative breast cancer. An intergroup study. , 1989, The New England journal of medicine.
[17] C. Redmond,et al. A randomized clinical trial evaluating sequential methotrexate and fluorouracil in the treatment of patients with node-negative breast cancer who have estrogen-receptor-negative tumors. , 1989, The New England journal of medicine.
[18] Donald E. Henson,et al. Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases , 1989 .
[19] A. Leong,et al. Immunoperoxidase Staining in the Detection of Lymph Node Metastases in Stage I Breast Cancer , 1989, Pathology.
[20] M. Zelen,et al. Prolonged disease-free survival after one course of perioperative adjuvant chemotherapy for node-negative breast cancer. , 1989, The New England journal of medicine.
[21] S. Silverberg,et al. Medullary carcinoma of the breast: a clinicopathologic study with appraisal of current diagnostic criteria. , 1988, Human pathology.
[22] C. Redmond,et al. Relative worth of estrogen or progesterone receptor and pathologic characteristics of differentiation as indicators of prognosis in node negative breast cancer patients: findings from National Surgical Adjuvant Breast and Bowel Project Protocol B-06. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] Jack Cuzick,et al. Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. An overview of 61 randomized trials among 28,896 women , 1988 .
[24] A. Goldhirsch,et al. Prognostic significance of peritumoral vessel invasion in clinical trials of adjuvant therapy for breast cancer with axillary lymph node metastasis. , 1985, Human pathology.
[25] A. Neville,et al. Prognostic significance of peritumoral vascular invasion in breast cancer. , 1984, British Journal of Cancer.
[26] P. Saigo,et al. Occult axillary lymph node metastases from breast cancers with intramammary lymphatic tumor emboli , 1982, The American journal of surgical pathology.
[27] R. Nissen-Meyer,et al. Surgical adjuvant chemotherapy. Results with one short course with cyclophosphamide after mastectomy for breast cancer , 1978, Cancer.
[28] P. Rosen,et al. Medullary carcinoma of the breast. A clinicopathologic study with 10 year follow‐up , 1977, Cancer.
[29] H. Thaler,et al. Prognostic significance of tumor emboli in intramammary lymphatics in patients with mammary carcinoma , 1977, The American journal of surgical pathology.
[30] B. Fisher,et al. The pathology of invasive breast cancer A Syllabus Derived from Findings of the National Surgical Adjuvant Breast Project (Protocol No. 4) , 1975, Cancer.
[31] D. Cox. Regression Models and Life-Tables , 1972 .
[32] I D Bross,et al. Cancer of the breast: Size of neoplasm and prognosis , 1969, Cancer.
[33] E. Kaplan,et al. Nonparametric Estimation from Incomplete Observations , 1958 .
[34] H. Bloom,et al. Histological Grading and Prognosis in Breast Cancer , 1957, British Journal of Cancer.